Pasithea Therapeutics Announces Opening Of Enrollment In The U.S. For Its Phase 1 Trial Of PAS-004
Pasithea Therapeutics Announces Opening Of Enrollment In The U.S. For Its Phase 1 Trial Of PAS-004
Pasithea Therapeutics 宣佈其 PAS-004 一期試驗在美國開放註冊
-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy --
— 激活 PAS-004 1 期臨床試驗的四個美國站點，以評估安全性、劑量、關鍵生物標誌物數據和初步療效——
-- Plans to open three additional sites in Eastern Europe in the coming months --
-計劃在未來幾個月內在東歐再開設三個基地-
-- Preliminary interim data expected in 2H 2024 --
--預計將在2024年下半年發佈初步中期數據--
SOUTH SAN FRANCISCO, Calif. and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced the activation of four clinical trial sites in the United States. These U.S. clinical trial sites...
加利福尼亞州南舊金山和邁阿密，2024 年 2 月 13 日（GLOBE NEWSWIRE）— Pasithea The...
登入免費觀看全文
登入/註冊